1 / 37

Sickle Cell Disease: Outpatient Management and Complications

Sickle Cell Disease: Outpatient Management and Complications. Hilary Suzawa Baylor Med/Peds June 16, 2008. Sickle Cell Disease. First described 1910 Ethnic backgrounds: Black (African) Mediterranean Arabian peninsula Indian subcontinent Caribbean South and Central America.

bela
Download Presentation

Sickle Cell Disease: Outpatient Management and Complications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sickle Cell Disease: Outpatient Management and Complications Hilary Suzawa Baylor Med/Peds June 16, 2008

  2. Sickle Cell Disease • First described 1910 • Ethnic backgrounds: • Black (African) • Mediterranean • Arabian peninsula • Indian subcontinent • Caribbean • South and Central America

  3. Hemoglobin S • Substitution of a valine for glutamic acid at the sixth amino acid of the beta globin chain • Produces a hemoglobin tetramer (alpha2/beta S2) that is poorly soluble when deoxygenated

  4. Variants • Hemoglobin SS (SCD-SS) • Hemoglobin SC (SCD-SC) • Sickle Beta Thalassemia • SCD-SB+thal or SCD-SB0 thal • In US ~2/3 of SCD are SCD-SS • SCD-SC or Sickle Beta Thalassemia may NOT have significant anemia

  5. Average Lifespan • Sickle Cell Disease (SCD-SS)— • 45 years • One generation ago average survival was as low as 14 years • SCD-SC or Sickle Beta Thalassemia— • 50-60 years

  6. Prenatal or Preconception • Amniocentesis if needed • Genetics evaluation • High-risk ob if needed • Maternal mortality <2% and neonatal mortality <5% • Increased risk of pre-eclampsia, pre-term labor, low-birth weight

  7. Birth-6 months • Visit Q2 months (2 wk, 2 mth, 4 mth, 6 mth) • CBC every visit • Heptavalent conjugated pneumococcal vaccine (Prevnar) at 2 mth, 4 mth, 6 mth • PCN VK 125 mg po BID starting at 2-3 mths

  8. 6 months-2 years • Visit Q3 months (6 mth, 9 mth, 12 mth, 15 mth, 18 mth, 21 mth, 2 yrs) • CBC every 3-6 mths • UA annually • Ferritin or serum iron and TIBC once at 1-2 yrs • BUN, Cr, LFTS once at age 1-2 yrs • Prevnar at 15 mths • Flu vaccine • Start folic acid daily at 1 year • Consultation with pedi heme

  9. 2 years • Screening with specialized Doppler US transcranial blood-flow velocity (TBV) • Recommended for asymptomatic children with sickle cell dz beginning at age 2 yrs • Recommended annually from 2-16 yrs age • TBV 200 cm/sec or more are at increased risk of stroke

  10. 2 years-5 years • Visit Q6 months • CBC at least yearly • UA at least yearly • BUN, Cr and LFTs every 1-2 yrs • 23-valent Pneumococcal vaccine (Pneumovax) at age 2 yrs; booster at age 5 yrs • Meningococcal vaccine after age 2 yrs • Flu vaccine annually • Increase PCN VK to 250 mg po BID at 3 yrs old

  11. >5 years • Visits Q6-12 months • CBC at least yearly • UA at least yearly • BUN, Cr and LFTs every 2-3 years • Flu vaccine yearly • Consider stop PCN VK • NOT if pt has had splenectomy OR h/o invasive pneumococcal infxn • Continue folic acid • Annual eye exam starting at 10 yrs (focus on retina)

  12. Growth • Decrease in height and weight compared to peers • During adolescent growth spurt begin to catch up with peers • Do NOT experience growth failure, only growth delay • Delayed puberty • Menarche delayed 2-2.5 years • Dysmenorrhea may precipitate pain episodes • Puberty, although delayed, proceeds normally once started

  13. Adolescence • Visits annually • CBC yearly • UA yearly • BUN, Cr and LFTs every 2-3 years • Ferritin or serum iron and TIBC at least once • Flu vaccine yearly • Transition from pediatric to adult care

  14. Adult • Biannual visit for pt >30 years • Annual eye exam • Vaccinations • Hepatitis vaccine • Pneumococcal vaccine (Pneumovax) • Evaluate for elevated BP and pulmonary HTN • Foot care and protective shoes • Consider PCN VK prophylaxis • Folic acid daily to ensure adequate amounts for high erythrocyte turnover • Consider hydroxyurea

  15. Pneumovax • First dose at 2 years • If pt <10 years, then give booster at age 3-5 years • If pt >10 years, then give booster 5 years after first dose • Support for a one time booster 5 years after first dose; some institutions give Q5 years

  16. Blood Pressure • Pt with SCD-SS have lower systolic and diastolic blood pressure compared to others • Modest increases in BP within the normal range for general population may indicate underlying renal dz

  17. Pulmonary Hypertension • Monitor for pulmonary hypertension • Unexplained dyspnea or hypoxemia • Loud P2 • Enlarged heart (RV) on CXR • Check Echo

  18. PCN VK prophylaxis • By age 2 months, start PCN VK 125 mg po BID • Age 3 years increase dose to PCN VK 250 mg po BID • Functional asplenia occurs <1 year age in pt with SCD-SS and SCD SB0thal • SCD-SS patients have usually infarcted their spleens before 4 years • Can be discontinued after age 5 years except in child who has had splenectomy or invasive infxn

  19. Hydroxyurea • Increases Hb F levels • Improves red cell deformability and hydration • Reduces red cell adhesion to vascular endothelium

  20. Blood Transfusion • Post-transfusion, Hb level should not exceed 10-11 g/dL • Check for infection: HIV, Hepatitis panel • Alloimmunization—in up to 30% of pt who receive frequent transfusions • Volume overload • Iron overload • Use of chelator • Exchange transfusion

  21. Clinical Case #1 • 2 yo AAM with h/o SCD-SS presents for sick visit. • On physical exam pt has palpable spleen not previously observed. • Pt’s baseline Hb ~8 but current Hb ~3 • Reticulocyte count increased from pt’s baseline

  22. Clinical Case #1 • What medical condition do you suspect? • Acute Splenic Sequestration Crisis: sudden enlargement of spleen, precipitous fall in Hct (at least 2 g/DL), rise in reticulocyte count. • What is most common age for this to develop? • Often occurs between 6 months and 3 years • Hb SS at age <3 years. Variants at any time during childhood.

  23. Clinical Case #1 • What treatment do you recommend? • Hospitalization • IVF +- blood transfusion • After first or second crisis, consider elective splenectomy when child is stable • Preventive education: Caretaker should know how to palpate for splenic size and know about risk of sequestration crisis

  24. Clinical Case #2 • 17 yo AAF with h/o RAD and SCD-SS was recently hospitalized for a vaso-occlusive pain crisis. Presents 1 week after discharge for hospital follow-up. • Now c/o minimal bilateral LE pain, chest discomfort, fever (T=100) • Pulse ox in the office Sat 88% on RA • Chest X-ray: Normal

  25. Clinical Case #2 • What medical condition do you suspect? • Acute Chest Syndrome • Ages birth-9 years • May be accompanied by or preceded by pain the chest or extremities, fever, respiratory distress and low O2 Sat • Hypoxemia is not necessary for dx • CXR may be normal initially with later development of infiltrate • 30% of all Hb SS pt will have one episode of Acute Chest Syndrome; ½ of these pt will have recurrent episodes • Asthma increases risk of ACS

  26. Clinical Case #3 • 5 yo AAM with SCD-SS disease presents with a new limp • What medical conditions would you consider? • What other information would you like to know?

  27. DDX Limp in Hb SS Disease • DDX • Osteomyelitis • Avascular Necrosis of the hip • Stroke • Other information: • H/o HA • Fever • Labs: WBC, ESR • Extremity exam, hip exam • Neuro exam

  28. AVN • Most common site of AVN • Femoral head • Humeral head • Knee • Small joints of hands and feet • Most common orthopedic complication in SCD and occurs in up to 50% of all pt • SCD is the most common cause of AVN in children

  29. Stroke • Stroke occurs in 7-11% of children with SCD • SCD-SS overall risk of stroke 3.75% throughout lifetime • <2 yrs have lowest incidence of stroke • 2-5 years have highest incidence infarctive stroke • 20-29 years have highest incidence hemorrhagic stroke

  30. Questions • What is the most common cause of osteomyelitis in pt with SCD-SS? • Salmonella #1, S. aureus #2 • How much does Hb usually drop with aplastic crisis? • >= 30% reduction from baseline Hb • What is the most common cause of aplastic crisis? • Parvovirus B19 causes ~70%

  31. Bacterial infection • What are most common bacteria causing infxn in SCD-SS? • Streptococcus pneumoniae • Staphylococcus aureus • Salmonella species • Haemophilus influenza type b • Escherichia coli • Klebsiella species

  32. Complications • Airway/Breathing • Acute chest syndrome • Chronic Pulmonary Hypertension • CNS • Stroke • Pain • Cardiovascular • Hypertension

  33. GI Complications • GI • Cholelithiasis, Choledocholithiasis, Acute Cholecystitis • Abdominal Pain Crisis • Sickle Hepatopathy • Pancreatitis • Peptic Ulcer Disease • Hematologic • Acute splenic sequestration crisis • Aplastic crisis • Blood transfusion complications • GU/Gyn • Priapism • Pregnancy Complications, need for Genetic Counseling

  34. Complications • Infection • Osteomyelitis • Renal Disease • Orthopedic • Aseptic Necrosis of the hip (AVN) • Chronic Leg Ulcers • Multiple Organ Failure Syndrome: • fever, decrease Hb, decrease plt, rhabdomyolysis, mental status changes

  35. Bibliography • Koshy, M and Dorn, L. “Continuing Care for Adult Patients with Sickle Cell Disease.” Hematology/Oncology Clinics of North America 1996; 10 (6): 1265-1273. • Lottenberg, R and Hassell, K. “An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease.” Hematology 2005; 58-65. • Mehta, S et al. “Opportunities to Improve Outcomes in Sickle Cell Disease.” American Family Physician 2006; 74 (2): 303-310.

  36. Bibliography • Redding-Lallinger, R and Knoll, C. “Sickle Cell Disease—Pathophysiology and Treatment.” Curr Probl Pediatr Adolesc Health Care 2006; 36: 346-376. • Wethers, D. “Sickle Cell Disease in Childhood: Part I. Laboratory Diagnosis, Pathophysiology and Health Maintenance.” American Family Physician 2000; 62 (5): 1013-1020.

  37. Bibliography • Wethers, D. “Sickle Cell Disease in Childhood: Part II. Diagnosis and Treatment of Major Complications and Recent Advances in Treatment.” American Family Physician 2000; 62 (6): 1309-1314.

More Related